Is Gilead Science stock a buy?

Is Gilead Science stock a buy?

We believe that Gilead Sciences stock (NASDAQ NDAQ +1.4% : GILD) is a good buying opportunity at the present time. GILD stock trades near $65 currently and it is, in fact, down 19% from its pre-Covid high of around $80 in March 2020 – before the coronavirus pandemic hit the world.

Who owns Gilead Sciences Inc?

Top 10 Owners of Gilead Sciences Inc

Stockholder	Stake	Shares owned
The Vanguard Group, Inc.	7.95%	99,724,620
BlackRock Fund Advisors	6.20%	77,779,661
SSgA Funds Management, Inc.	4.33%	54,299,659
Capital Research & Management Co….	3.15%	39,436,987

What do analysts say about Gilead stock?

The 21 analysts offering 12-month price forecasts for Gilead Sciences Inc have a median target of 75.00, with a high estimate of 100.00 and a low estimate of 63.00. The median estimate represents a +14.05% increase from the last price of 65.76.

Is GILD worth buying?

Valuation metrics show that Gilead Sciences, Inc. may be undervalued. Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of GILD, demonstrate its potential to outperform the market.

Is Gilead a good long term investment?

But while there may be a waiting period before results are seen, Gilead remains a fantastic long-term buy due to its valuation. Right now, the stock has a 4.3% dividend yield and trades for just 3.4 times sales and 9.8 times free cash flow.

Should I hold Gilead?

There are currently 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Gilead Sciences stock.

What is Gilead net worth?

Gilead Sciences

Type	Public
Net income	US$5.39 billion (2019)
Total assets	US$61.63 billion (2019)
Total equity	US$22.65 billion (2019)
Number of employees	11,800 (2019)